查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1931288

2026-2032年全球肺炎鏈球菌13價結合疫苗市場（依最終用戶、適應症及劑型分類）預測

Pneumococcal 13-valent Conjugate Vaccine Market by End User, Indication, Formulation - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年肺炎鏈球菌13價結合疫苗市場規模為39.8億美元，預計2026年將達42億美元，到2032年將達到62.3億美元，複合年成長率為6.59%。

主要市場統計數據
基準年 2025 39.8億美元
預計年份：2026年 42億美元
預測年份：2032年 62.3億美元
複合年成長率 (%) 6.59%

目前13價肺炎鏈球菌疫苗環境的重點方向：明確臨床價值、營運重點與策略決策點

肺炎鏈球菌感染仍然是所有年齡層中疫苗可預防疾病和死亡的主要原因，13價結合疫苗仍然是許多免疫接種計劃中預防策略的基石。本文將PCV13置於更廣泛的免疫生態系統中，重點闡述了該疫苗在常規兒童免疫接種計劃、成人加強免疫策略以及針對高危險群的公共衛生宣傳活動中的作用。監管核准情況的變化、高劑量疫苗的出現以及採購政策的轉變，都導致了競爭格局和項目選擇的變化。

技術創新、包裝差異化和採購重點的轉變如何重塑PCV13疫苗的競爭策略和專案選擇

肺炎鏈球菌疫苗市場正經歷著變革性的轉變，其促進因素包括結合疫苗設計的技術進步、監管預期的變化以及公共和私人支付方採購方式的改變。新型高劑量疫苗的出現促使人們重新評估現有的免疫接種方案，進而影響了對傳統13價疫苗的需求。同時，生產商正透過包裝創新實現差異化，例如預填充式注射器以方便即時接種，以及推出多劑量管瓶以支持資源匱乏環境下的大規模宣傳活動。這些包裝選擇影響低溫運輸物流和接種效率，進而影響整個醫療保健系統的採購重點。

評估截至2025年的累積關稅如何加速疫苗供應鏈的來源多元化、採購流程重組和包裝權衡。

美國在2025年前實施的累積關稅及相關貿易應對措施，促使疫苗供應鏈各環節重新評估籌資策略、製造地及採購時間表。製造商和經銷商正透過供應商多元化、將部分生產流程轉移到更靠近終端市場的地方以及重新談判合約條款來應對，以減輕額外進口成本對下游採購商的影響。這些供應面的調整對庫存管理政策和競標計劃週期產生了連鎖反應，促使公共和私人採購商尋求透過長期合約和本地生產夥伴關係來獲得更可靠的供應保障。

詳細的細分分析揭示了不同年齡層、最終用戶、分銷管道、適應症和製劑形式之間存在的明顯臨床優先事項、採購行為和分銷要求。

細分市場分析表明，不同年齡層、最終用戶、分銷管道、適應症和劑型的需求促進因素和營運重點各不相同，凸顯了製定客製化商業策略的必要性。依年齡層別分類，13-17歲青少年、18-49歲成年人、2-12歲兒童、0-2歲嬰兒和50歲以上老年人的臨床需求和疫苗接種接觸點各不相同。這意味著臨床訊息、接種方案和推廣策略必須根據各年齡層的醫療環境和支付方的期望進行調整。最終用戶的細分導致了採購週期和合約要求的差異，這主要是由於私營和公共部門採購者的差異造成的。民營市場優先考慮便利性和分銷管道的激活，而公共項目則優先考慮成本效益、低溫運輸效率和公平覆蓋。

區域監管差異、採購機制和衛生系統能力如何推動重點區域採用不同的管道和項目優先事項？

區域動態影響籌資策略、監管參與以及專案交付管道的優先排序，每個區域都有其獨特的營運實際情況和相關人員的期望。在美洲，免疫規劃力求在集中採購與不斷擴大的私部門活動和藥房供應之間取得平衡，從而支持成人疫苗接種工作，並確保都市區兒童疫苗的廣泛普及。在許多市場，過渡性法規結構和已建立的低溫運輸基礎設施使得包裝創新得以快速應用，但農村地區的疫苗可及性和健康公平性仍然是計畫面臨的關鍵挑戰。

競爭優勢需要結合傳統臨床信譽、策略製造夥伴關係和通路特定商業化，以實現競爭定位。

PCV13疫苗市場的競爭格局融合了傳統的產品管理、策略性的生命週期管理以及生產合作夥伴和經銷商之間的協作。現有生產者不斷累積臨床數據和真實世界證據，以支持各年齡層的常規免疫接種，但新參與企業和高滴度疫苗的出現迫使現有生產商重新定義其差異化提案，而這些優勢的核心在於疫苗的適用性、接種成本和供應安全。隨著企業尋求應對產能限制並降低貿易中斷風險，包括契約製造和區域灌裝包裝夥伴關係在內的協作安排正變得越來越普遍。

採取切實可行的策略行動，增強供應鏈韌性，收集證據，並針對特定管道實現商業化，同時與公共衛生優先事項保持一致。

產業領導者應優先考慮供應鏈韌性、合規性和差異化價值提案，以避免市場萎縮風險並抓住策略機會。透過購買多元化和區域性填充包裝合約提高生產柔軟性，可以降低關稅相關成本並縮短前置作業時間。同時，使監管申報和上市後證據的生成與區域監管預期保持一致，可以加快專案實施並增強競爭性競標。在商業方面，企業應根據特定終端使用者和分銷管道客製化產品和服務，確保包裝和培訓材料能夠滿足各個場所（例如政府診所、醫院藥房、零售藥房和電商履約網路）的實際情況。

採用嚴謹的混合方法調查方法，整合相關人員訪談、監管審查和證據三角驗證，以得出可操作的專案見解。

本執行摘要摘要的研究整合了一級資訊來源和二級資訊來源，透過對監管文件、同行評審的臨床文獻、採購文件和相關人員訪談進行三角驗證，從而對PCV13市場趨勢檢驗全面的了解。一級資訊來源包括對免疫專案經理、醫院藥屋主任、商業負責人和分銷專家的結構化訪談，以了解決策促進因素、物流限制和採購標準。第二手資料涵蓋了監管指南、已發表的疫苗效力研究以及對不同醫療機構低溫運輸和給藥實踐的營運分析。研究人員還審查了來自監測網路和公共衛生報告的數據，以了解流行病學趨勢的背景，從而為隊列優先排序和計畫實施時間決策提供基礎。

綜合考慮臨床意義、營運權衡和策略重點，我們重點闡述了相關人員如何協調一致以維持有效的肺炎球菌疫苗接種計劃。

本執行摘要指出，儘管PCV13疫苗在多個年齡層中仍是重要的臨床工具，但其未來的部署正受到包裝選擇、供應鏈趨勢和採購行為的影響。相關人員必須權衡多劑量管瓶和預填充式注射器之間的利弊，平衡近期宣傳活動的需求與可靠的供應，並調整商業策略以滿足公共和私營部門的不同期望。貿易政策變化帶來的累積效應進一步凸顯了在地化生產和多元化供應管道的必要性，以確保疫苗供應的連續性，並保護免疫接種計劃免受干擾。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依最終用戶分類的13價肺炎鏈球菌結合疫苗市場

  • 私部門
  • 公共部門

9. 依適應症分類的13價肺炎鏈球菌結合疫苗市場

  • 加強疫苗接種
  • 補種疫苗
  • 首次接種疫苗

10. 肺炎鏈球菌13價結合疫苗市場（以劑型分類）

  • 多劑量管瓶
  • 預填充式注射器

11. 各地區13價肺炎鏈球菌結合疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 肺炎鏈球菌13價結合疫苗市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各國13價肺炎鏈球菌結合疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國13價肺炎鏈球菌結合疫苗市場

17. 中國13價肺炎鏈球菌結合疫苗市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Biological E. Limited
  • Chongqing Taibang Biological Products Co., Ltd.
  • GlaxoSmithKline plc
  • Inventprise
  • Merck & Co., Inc.
  • Panacea BIoTec Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • SK bioscience Co., Ltd.
  • Vaxcyte
  • Walvax BIoTechnology Co., Ltd.
Product Code: MRR-7B550E008E0C

The Pneumococcal 13-valent Conjugate Vaccine Market was valued at USD 3.98 billion in 2025 and is projected to grow to USD 4.20 billion in 2026, with a CAGR of 6.59%, reaching USD 6.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.98 billion
Estimated Year [2026] USD 4.20 billion
Forecast Year [2032] USD 6.23 billion
CAGR (%) 6.59%

A focused orientation to the current pneumococcal 13-valent vaccine environment clarifying clinical value, operational priorities, and strategic decision points

Pneumococcal disease remains a leading cause of vaccine-preventable morbidity and mortality across age cohorts, and the 13-valent conjugate vaccine continues to be a cornerstone of prevention strategies in many immunization schedules. This introduction situates the PCV13 landscape within a broader immunization ecosystem, highlighting the vaccine's role in routine pediatric schedules, adult revaccination strategies, and targeted public health campaigns aimed at at-risk populations. Recent shifts in regulatory approvals, the emergence of higher-valent alternatives, and evolving procurement preferences have collectively altered competitive dynamics and programmatic choices.

Understanding the current environment requires attention to supply chain resilience, packaging preferences such as multi-dose vials versus pre-filled syringes, and the complex interplay between public sector tenders and private market demand. Moreover, demographic transitions and changing disease epidemiology influence priority populations, with older adults and infants continuing to be focal points for immunization efforts. This section frames the subsequent analysis by clarifying the vaccine's clinical rationale, operational considerations in administration and storage, and the strategic questions that stakeholders must address to optimize uptake and program impact. Transitional discussion will connect these foundational considerations to segmentation, regional nuances, and competitive behavior addressed later in the executive summary.

How technological innovation, packaging differentiation, and shifting procurement priorities are reshaping competitive strategies and programmatic choices in the PCV13 landscape

The pneumococcal vaccine landscape is experiencing transformative shifts driven by technological advances in conjugate design, evolving regulatory expectations, and changing procurement practices among public and private payers. Newer higher-valent vaccines have prompted reassessments of existing immunization schedules, which in turn influences demand for legacy 13-valent products. At the same time, manufacturers are differentiating through packaging innovations, such as pre-filled syringes for point-of-care convenience and multi-dose vials to support mass campaigns in resource-constrained settings. These packaging choices affect cold-chain logistics and administration efficiency, thereby shaping procurement preferences across health systems.

Concurrently, policy and payer trends are encouraging value-based evaluation of vaccines, emphasizing real-world effectiveness, herd protection, and reduced healthcare utilization. Public sector procurers are increasingly focused on tender structures that reward supply reliability and total cost of administration rather than unit price alone. Private sector channels are adapting through digital engagement and pharmacy-based immunization programs that improve access but require consistent supply and physician education. As a result, competitive strategies are shifting from purely clinical messaging to integrated offerings that combine product, packaging, and service elements to meet diverse stakeholder needs. The next sections explore how these shifts interact with regional dynamics and segmentation nuances to define future opportunities and risks.

Assessing how cumulative tariff measures through 2025 have accelerated supply diversification, procurement reengineering, and packaging trade-offs across vaccine supply chains

Cumulative tariff measures implemented in the United States and related trade responses through 2025 have driven a reassessment of sourcing strategies, manufacturing footprints, and procurement timelines across the vaccine supply chain. Manufacturers and distributors have responded by diversifying suppliers, relocating certain production steps closer to end markets, and renegotiating contractual terms to mitigate the impact of added import costs on downstream purchasers. These supply-side adjustments have had ripple effects on inventory management policies and tender planning horizons, prompting both public and private buyers to seek greater supply assurance through longer-term agreements or local manufacturing partnerships.

For immunization programs, the tariff environment has amplified the importance of packaging format decisions; multi-dose vials, which lower per-dose handling costs and cold-chain footprint, are juxtaposed against pre-filled syringes that offer ease of use but higher unit logistics costs. Procurement bodies are increasingly incorporating total administration cost assessments into purchasing criteria to balance these trade-offs. Moreover, transitional contingency planning has become central to procurement governance, encouraging stakeholders to build flexibility into ordering cycles and to prioritize transparency in supplier reporting. Ultimately, the cumulative tariff environment has accelerated structural changes in supply chain resilience and procurement behavior that will influence how PCV13 is sourced, distributed, and administered through the near term.

Granular segmentation reveals distinct clinical priorities, procurement behaviors, and distribution requirements across age cohorts, end users, channels, indications, and formulations

Segmentation insights reveal how demand drivers and operational priorities vary by age, end user, distribution channel, indication, and formulation, underscoring the need for tailored commercial approaches. Based on age group, populations of Adolescents 13-17 Years, Adults 18-49 Years, Children 2-12 Years, Infants 0-2 Years, and Older Adults 50+ Years each exhibit distinct clinical priorities and immunization touchpoints, meaning that clinical messaging, dosing schedules, and outreach tactics must be calibrated to age-specific care settings and payer expectations. Based on end user, the dichotomy between Private Sector and Public Sector purchasers produces divergent procurement cycles and contractual requirements; private markets often emphasize convenience and channel activation, whereas public programs prioritize cost-effectiveness, cold-chain efficiency, and equitable coverage.

Based on distribution channel, platforms such as E-Commerce Platforms, Government Clinics, Hospital Pharmacies, and Retail Pharmacies require differentiated availability strategies, temperature-controlled logistics, and educational materials tailored to point-of-care staff. Based on indication, whether the focus is Booster Immunization, Catch-Up Immunization, or Primary Immunization determines dosing schedules, target cohorts, and monitoring needs, with catch-up campaigns demanding higher short-term volume and booster strategies relying on robust adult uptake channels. Based on formulation, the choice between Multi-Dose Vial and Pre-Filled Syringe influences procurement preferences, waste management practices, and on-site handling capabilities. Integrating these segmentation dimensions enables more precise targeting of evidence generation, commercial incentives, and operational investments across stakeholders.

How regional regulatory diversity, procurement mechanisms, and health system capabilities are driving differentiated adoption paths and program priorities across major geographies

Regional dynamics shape prioritization of procurement strategies, regulatory engagement, and program implementation pathways, with each geography presenting unique operational realities and stakeholder expectations. In the Americas, immunization programs balance centralized procurement with growing private sector activity and pharmacy-based delivery, which supports adult revaccination efforts and broad access to pediatric immunizations in urban centers. Transitional regulatory frameworks and established cold-chain infrastructure in many markets enable rapid adoption of packaging innovations, although rural access and health equity remain central programmatic concerns.

In Europe, Middle East & Africa, regulatory heterogeneity and divergent purchasing mechanisms create a patchwork of adoption timelines; some countries employ joint procurement frameworks and sophisticated surveillance systems while others face logistical constraints that influence the preference for multi-dose vials to maximize coverage. Policy makers in these regions emphasize cost-effectiveness and supply security alongside efforts to strengthen immunization registries. Meanwhile, in Asia-Pacific, rapid urbanization, expanding private healthcare spending, and concentrated manufacturing capacity have fostered both competitive manufacturing investments and demand segmentation between public tenders and private clinic channels. Cross-cutting themes across all regions include the need for stronger surveillance data to guide program adjustments and the importance of supply chain resilience to sustain immunization continuity.

Competitive positioning blends legacy clinical credibility, strategic manufacturing partnerships, and channel-specific commercialization to secure programmatic advantage

Competitive dynamics within the PCV13 landscape reflect a blend of legacy product stewardship, strategic lifecycle management, and collaboration across manufacturing partners and distributors. Established manufacturers continue to maintain clinical and real-world evidence dossiers that support routine use across age cohorts, while new entrants and higher-valent alternatives are prompting incumbent players to articulate differentiating propositions focused on programmatic fit, cost of administration, and supply reliability. Collaborative arrangements, including toll-manufacturing and regional fill-finish partnerships, have become more prevalent as companies seek to manage capacity constraints and reduce exposure to trade disruptions.

Manufacturers are also investing in post-marketing surveillance and health economics studies to demonstrate broader public health value, including indirect protection and reductions in healthcare utilization. On the commercial side, firms are exploring channel-specific strategies that engage hospital systems, retail pharmacies, and digital platforms to enhance access and adherence, particularly for adult booster programs. Strategic alliances with local distributors and targeted education campaigns for immunizers support market penetration in heterogeneous regulatory environments. As a result, competitive advantage increasingly derives from a combination of clinical credibility, operational agility, and the ability to offer integrated solutions that align with purchaser priorities rather than from product attributes alone.

Practical strategic actions to fortify supply resilience, evidence generation, and channel-specific commercialization while aligning with public health priorities

Industry leaders should prioritize supply resilience, regulatory alignment, and differentiated value propositions to navigate displacement risk and capture strategic opportunities. Strengthening manufacturing flexibility through diversified sourcing and regional fill-finish agreements will reduce exposure to tariff-related costs and shorten lead times. At the same time, aligning regulatory submissions and post-marketing evidence generation with regional authority expectations accelerates program inclusion and supports tender competitiveness. Commercially, firms should tailor offerings to distinct end users and distribution channels, ensuring that packaging and training materials address the operational realities of government clinics, hospital pharmacies, retail pharmacies, and e-commerce fulfillment networks.

Additionally, companies should expand collaborations with public health agencies to co-design catch-up campaigns and adult booster strategies that leverage existing immunization platforms. Investing in real-world effectiveness studies and health economic modeling will strengthen value narratives for payers and procurement bodies while enabling outcome-based contracting conversations. Finally, improving digital engagement for both clinicians and patients will support adherence to multi-dose schedules and booster uptake. By integrating these priorities into a cohesive strategic plan, leaders can protect existing franchises, facilitate responsible lifecycle management, and unlock new channels for sustainable uptake.

A rigorous mixed-methods research approach integrating stakeholder interviews, regulatory review, and evidence triangulation to produce actionable programmatic insights

The research underpinning this executive summary synthesizes primary and secondary sources, triangulating regulatory filings, peer-reviewed clinical literature, procurement documentation, and stakeholder interviews to build a robust view of the PCV13 landscape. Primary inputs included structured interviews with immunization program managers, hospital pharmacy directors, commercial leaders, and distribution specialists to capture decision drivers, logistical constraints, and procurement criteria. Secondary research encompassed regulatory guidance, published vaccine effectiveness studies, and operational analyses of cold-chain and administration practices in diverse healthcare settings. Data from surveillance networks and public health reports were reviewed to contextualize epidemiologic trends that inform cohort prioritization and program timing.

Analytical methods combined qualitative thematic analysis with scenario-based assessments to evaluate the implications of tariffs, packaging preferences, and distribution channel shifts. Cross-validation procedures were applied to ensure consistency across stakeholder perspectives and documentary evidence, and limitations were transparently acknowledged where data granularity or recent policy changes constrained inference. The research approach emphasized practical relevance for commercial and public health decision makers, focusing on actionable insights rather than predictive metrics, and prioritized evidence that directly informs procurement, supply chain, and implementation strategies.

Synthesis of clinical relevance, operational trade-offs, and strategic priorities that stakeholders must align to sustain effective pneumococcal immunization programs

This executive synthesis underscores that the PCV13 vaccine remains a clinically important tool across multiple age cohorts, but its future trajectory is being reshaped by packaging choices, supply chain dynamics, and procurement behavior. Stakeholders must reconcile the trade-offs between multi-dose vials and pre-filled syringes, balance short-term campaign needs against steady-state supply reliability, and adapt commercial strategies to meet distinct public and private sector expectations. The cumulative effect of trade policy changes has reinforced the need for regional manufacturing and diversified supply channels to maintain continuity of access and protect immunization programs from disruption.

Looking ahead, successful programs will be those that combine sound clinical evidence with pragmatic operational planning and collaborative procurement frameworks. Decision makers should continue to invest in surveillance and health economic evidence to guide cohort prioritization while ensuring that logistical choices support equitable access. By aligning manufacturing, regulatory, and commercial approaches, stakeholders can uphold the public health benefits of pneumococcal immunization and respond nimbly to a changing competitive and policy landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumococcal 13-valent Conjugate Vaccine Market, by End User

  • 8.1. Private Sector
  • 8.2. Public Sector

9. Pneumococcal 13-valent Conjugate Vaccine Market, by Indication

  • 9.1. Booster Immunization
  • 9.2. Catch-Up Immunization
  • 9.3. Primary Immunization

10. Pneumococcal 13-valent Conjugate Vaccine Market, by Formulation

  • 10.1. Multi-Dose Vial
  • 10.2. Pre-Filled Syringe

11. Pneumococcal 13-valent Conjugate Vaccine Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Pneumococcal 13-valent Conjugate Vaccine Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Pneumococcal 13-valent Conjugate Vaccine Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Pneumococcal 13-valent Conjugate Vaccine Market

15. China Pneumococcal 13-valent Conjugate Vaccine Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Biological E. Limited
  • 16.6. Chongqing Taibang Biological Products Co., Ltd.
  • 16.7. GlaxoSmithKline plc
  • 16.8. Inventprise
  • 16.9. Merck & Co., Inc.
  • 16.10. Panacea Biotec Ltd.
  • 16.11. Pfizer Inc.
  • 16.12. Sanofi S.A.
  • 16.13. Serum Institute of India Pvt. Ltd.
  • 16.14. Shenzhen Kangtai Biological Products Co., Ltd.
  • 16.15. SK bioscience Co., Ltd.
  • 16.16. Vaxcyte
  • 16.17. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIVATE SECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIVATE SECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIVATE SECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PUBLIC SECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PUBLIC SECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PUBLIC SECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY BOOSTER IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY BOOSTER IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY BOOSTER IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY CATCH-UP IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY CATCH-UP IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY CATCH-UP IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIMARY IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIMARY IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRIMARY IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY MULTI-DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. AMERICAS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 28. AMERICAS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 29. AMERICAS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 30. AMERICAS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 31. NORTH AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. NORTH AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. NORTH AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 34. NORTH AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 35. LATIN AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. LATIN AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. LATIN AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 38. LATIN AMERICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 39. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 40. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 42. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 43. EUROPE PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. EUROPE PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. EUROPE PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 46. EUROPE PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 47. MIDDLE EAST PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. MIDDLE EAST PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. MIDDLE EAST PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. MIDDLE EAST PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 51. AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 54. AFRICA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. ASEAN PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. ASEAN PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. ASEAN PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 63. ASEAN PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 64. GCC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GCC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GCC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 67. GCC PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPEAN UNION PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPEAN UNION PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPEAN UNION PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPEAN UNION PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 72. BRICS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. BRICS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. BRICS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. BRICS PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 76. G7 PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. G7 PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. G7 PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. G7 PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 80. NATO PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NATO PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NATO PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NATO PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. UNITED STATES PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. UNITED STATES PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. UNITED STATES PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. UNITED STATES PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. CHINA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. CHINA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. CHINA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. CHINA PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)